JP2006521098A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006521098A5 JP2006521098A5 JP2006504332A JP2006504332A JP2006521098A5 JP 2006521098 A5 JP2006521098 A5 JP 2006521098A5 JP 2006504332 A JP2006504332 A JP 2006504332A JP 2006504332 A JP2006504332 A JP 2006504332A JP 2006521098 A5 JP2006521098 A5 JP 2006521098A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- substitution
- amino acid
- group
- modification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000006467 substitution reaction Methods 0.000 claims 12
- 230000004048 modification Effects 0.000 claims 11
- 238000012986 modification Methods 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 238000001727 in vivo Methods 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 238000003780 insertion Methods 0.000 claims 5
- 230000037431 insertion Effects 0.000 claims 5
- 208000032843 Hemorrhage Diseases 0.000 claims 4
- 208000034158 bleeding Diseases 0.000 claims 4
- 230000000740 bleeding effect Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000013595 glycosylation Effects 0.000 claims 4
- 238000006206 glycosylation reaction Methods 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 208000031220 Hemophilia Diseases 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- 230000004988 N-glycosylation Effects 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 230000004989 O-glycosylation Effects 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 102220253478 rs1553261891 Human genes 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45654703P | 2003-03-20 | 2003-03-20 | |
| US60/456,547 | 2003-03-20 | ||
| US47970803P | 2003-06-19 | 2003-06-19 | |
| US60/479,708 | 2003-06-19 | ||
| PCT/DK2004/000193 WO2004083361A2 (en) | 2003-03-20 | 2004-03-22 | FVII OR FVIIa VARIANTS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011160400A Division JP2012095641A (ja) | 2003-03-20 | 2011-07-22 | ＦＶＩＩおよびＦＶＩＩａの変種 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006521098A JP2006521098A (ja) | 2006-09-21 |
| JP2006521098A5 true JP2006521098A5 (enExample) | 2007-05-10 |
| JP4847856B2 JP4847856B2 (ja) | 2011-12-28 |
Family
ID=33032721
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006504332A Expired - Fee Related JP4847856B2 (ja) | 2003-03-20 | 2004-03-22 | ＦＶＩＩおよびＦＶＩＩａの変種 |
| JP2011160400A Pending JP2012095641A (ja) | 2003-03-20 | 2011-07-22 | ＦＶＩＩおよびＦＶＩＩａの変種 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011160400A Pending JP2012095641A (ja) | 2003-03-20 | 2011-07-22 | ＦＶＩＩおよびＦＶＩＩａの変種 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7771996B2 (enExample) |
| EP (2) | EP2085470B1 (enExample) |
| JP (2) | JP4847856B2 (enExample) |
| AT (1) | ATE431403T1 (enExample) |
| AU (2) | AU2004221761B2 (enExample) |
| CA (1) | CA2519873C (enExample) |
| DE (1) | DE602004021099D1 (enExample) |
| DK (2) | DK2085470T3 (enExample) |
| ES (2) | ES2327044T3 (enExample) |
| WO (1) | WO2004083361A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7247708B2 (en) | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| WO2001058935A2 (en) | 2000-02-11 | 2001-08-16 | Maxygen Aps | FACTOR VII OR VIIa-LIKE MOLECULES |
| US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7812132B2 (en) | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US20030211094A1 (en) | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| DE60334983D1 (de) * | 2002-04-30 | 2010-12-30 | Bayer Healthcare Llc | Faktor vii oder faktor viia polypeptidvarianten |
| EP2085470B1 (en) | 2003-03-20 | 2012-05-16 | Bayer HealthCare LLC | FVII or FVIIa variants |
| JP4915918B2 (ja) * | 2003-06-19 | 2012-04-11 | バイエル ヘルスケア エルエルシー | 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種 |
| RU2396347C2 (ru) | 2004-08-17 | 2010-08-10 | Ксл Бехринг Гмбх | Модифицированные витамин к-зависимые полипептиды |
| WO2006114105A2 (en) * | 2005-04-26 | 2006-11-02 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
| US8633300B2 (en) | 2005-06-17 | 2014-01-21 | Novo Nordisk Healthcare Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
| JP5147692B2 (ja) | 2005-07-13 | 2013-02-20 | ノボ ノルディスク ヘルス ケア アーゲー | 治療用タンパク質生成のための宿主細胞タンパク質ノックアウト細胞 |
| CN101268185B (zh) | 2005-09-01 | 2013-03-27 | 诺沃-诺迪斯克保健股份有限公司 | 因子ⅶ多肽的疏水作用色谱纯化 |
| JP5690047B2 (ja) | 2005-09-14 | 2015-03-25 | ノボ ノルディスク ヘルス ケア アーゲー | ヒト凝固第ｖｉｉ因子ポリペプチド |
| DK2004214T3 (da) * | 2006-03-16 | 2013-02-18 | Stellaris Pharmaceuticals Aps | Lokalbehandling med faktor VII |
| US20100056428A1 (en) | 2006-09-01 | 2010-03-04 | Novo Nordisk Health Care Ag | Modified proteins |
| AU2013204377B2 (en) * | 2007-04-13 | 2015-07-16 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides and uses thereof |
| RU2571931C2 (ru) * | 2007-04-13 | 2015-12-27 | Каталист Биосайенсис, Инк. | Полипептиды на основе модифицированного фактора vii и их применение |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| TWI595004B (zh) | 2010-11-03 | 2017-08-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| DK3165232T3 (da) * | 2012-12-24 | 2019-09-16 | Coagulant Therapeutics Corp | Faktor vii-polypeptider med kortvarig virkning |
| KR20200057051A (ko) | 2017-09-27 | 2020-05-25 | 시질론 테라퓨틱스, 인크. | 활성 세포를 포함하는 방법, 조성물 및 이식 가능한 요소 |
| WO2019195056A1 (en) | 2018-04-04 | 2019-10-10 | Sigilon Therapeutics, Inc. | Methods, compositions, and implantable elements comprising stem cells |
| CN112203646A (zh) | 2018-04-04 | 2021-01-08 | 西吉隆医疗股份有限公司 | 可植入颗粒和相关方法 |
| UY38389A (es) | 2018-09-27 | 2020-04-30 | Sigilon Therapeutics Inc | Dispositivos implantables para terapia celular y métodos relacionados |
| EP3833381B1 (en) | 2019-08-15 | 2022-08-03 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration |
| EP4061942A4 (en) | 2019-11-22 | 2023-12-20 | Sigilon Therapeutics, Inc. | MONOCLONAL CELL LINES EXPRESSING AN EXOGENEOUS SUBSTANCE AND THEIR USES |
| CN120659872A (zh) | 2022-10-11 | 2025-09-16 | 西吉隆医疗股份有限公司 | 用于治疗疾病的经工程化的细胞和可植入元件 |
| WO2024081309A1 (en) | 2022-10-11 | 2024-04-18 | Sigilon Therapeutics, Inc. | Engineered cells and implantable elements for treatment of disease |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| US5180583A (en) | 1985-11-26 | 1993-01-19 | Hedner Ulla K E | Method for the treatment of bleeding disorders |
| US5258288A (en) | 1986-07-25 | 1993-11-02 | Genzyme Corporation | Vector containing DNA encoding mature human protein S |
| DK323587D0 (da) | 1987-06-25 | 1987-06-25 | Novo Industri As | Protein |
| EP0296413A2 (en) | 1987-06-12 | 1988-12-28 | Hoechst Japan Limited | Hybrid protein C and method for its preparation |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5648254A (en) | 1988-01-15 | 1997-07-15 | Zymogenetics, Inc. | Co-expression in eukaryotic cells |
| JPH0246296A (ja) | 1988-08-09 | 1990-02-15 | Hoechst Japan Ltd | 雑種プロテインｃ及びその製造方法 |
| US5218092A (en) | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
| US5041376A (en) | 1988-12-09 | 1991-08-20 | The Board Of Regents Of The University Of Texas System | Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins |
| US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| US5093317A (en) | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
| US5077214A (en) | 1989-07-07 | 1991-12-31 | The Texas A&M University System | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells |
| US5580560A (en) | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| US5225537A (en) | 1989-12-29 | 1993-07-06 | Zymogenetics, Inc. | Methods for producing hybrid phospholipid-binding proteins |
| FI923347A0 (fi) | 1990-01-26 | 1992-07-23 | Immuno Ag | Blodfaktorer producerade med rekombinant-dna-teknik och foerfarande foer expression av naemnda blodfaktorer samt i naemnda foerfarande anvaenda rekombinanta kokoppvirus. |
| ATE180834T1 (de) | 1990-01-29 | 1999-06-15 | Zymogenetics Inc | Antikoagulierende proteine |
| US5583107A (en) | 1990-09-04 | 1996-12-10 | Cor Therapeutics, Inc. | Agents affecting thrombosis and hemostasis |
| US5531916A (en) | 1990-10-03 | 1996-07-02 | E. I. Du Pont De Nemours And Company | Hydrofluorocarbon cleaning compositions |
| EP0785273A1 (en) | 1990-11-26 | 1997-07-23 | Genetics Institute, Inc. | Paired basic amino acid converting enzyme and DNA sequence encoding it |
| EP1479395A1 (en) | 1991-02-28 | 2004-11-24 | Novo Nordisk A/S | Modified factor VII |
| US5833982A (en) | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
| US5861374A (en) | 1991-02-28 | 1999-01-19 | Novo Nordisk A/S | Modified Factor VII |
| US5817788A (en) | 1991-02-28 | 1998-10-06 | Zymogenetics, Inc. | Modified factor VII |
| US5788965A (en) | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
| US5504064A (en) | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
| JPH0720127A (ja) | 1993-05-07 | 1995-01-24 | Eisai Co Ltd | 各種ｐｉｖｋａの測定方法および測定試薬 |
| AU703110B2 (en) | 1993-05-21 | 1999-03-18 | Novo Nordisk A/S | Modified factor VII |
| DE19531637A1 (de) | 1995-08-28 | 1997-03-06 | Immuno Ag | Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung |
| ATE321846T1 (de) | 1996-11-08 | 2006-04-15 | Oklahoma Med Res Found | Verwendung eines modifizierten protein-c |
| US5837843A (en) | 1996-11-08 | 1998-11-17 | Oklahoma Medical Research Foundation | Modified protein C |
| US6132729A (en) * | 1997-01-22 | 2000-10-17 | Board Of Regents, The University Of Texas System | Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment |
| AU5773798A (en) | 1997-01-29 | 1998-08-18 | Polymasc Pharmaceuticals Plc | Pegylation process |
| AU740207B2 (en) | 1997-02-06 | 2001-11-01 | Novozymes A/S | Polypeptide-polymer conjugates having added and/or removed attachment groups |
| US6475725B1 (en) | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
| AT407255B (de) | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
| ATE375363T1 (de) | 1997-07-14 | 2007-10-15 | Bolder Biotechnology Inc | Derivate des wachstumshormons und verwandte proteine |
| ES2339196T3 (es) | 1997-07-18 | 2010-05-17 | Novo Nordisk Health Care Ag | Uso de fviia o fviiai para el tratamiento de disfuncion endotelial y para la inhibicion de angiogenesis, respectivamente. |
| US6017882A (en) | 1997-10-23 | 2000-01-25 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7247708B2 (en) | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6693075B1 (en) | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| DE69936409T2 (de) | 1998-04-28 | 2008-04-17 | Laboratoires Serono S.A., Coinsins | Verfahren zur schrittweise Bindung von Polyethylenglykol (PEG) an Polypeptide |
| AT408613B (de) | 1998-06-17 | 2002-01-25 | Immuno Ag | Pharmazeutisches faktor vii-präparat |
| ATE263778T1 (de) | 1998-10-30 | 2004-04-15 | Novozymes As | Niedrigallergene proteinvarianten |
| CA2348822A1 (en) | 1998-10-30 | 2000-05-11 | Novozymes A/S | Glycosylated proteins having reduced allergenicity |
| JP4463988B2 (ja) | 1998-11-06 | 2010-05-19 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Ｖｉｉ因子の生産方法 |
| WO2000054787A1 (en) | 1999-03-16 | 2000-09-21 | The Children's Hospital Of Philadelphia | Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors |
| WO2001058935A2 (en) | 2000-02-11 | 2001-08-16 | Maxygen Aps | FACTOR VII OR VIIa-LIKE MOLECULES |
| US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| JP5090605B2 (ja) * | 2000-05-03 | 2012-12-05 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 凝固因子ｖｉｉの皮下投与 |
| WO2001083725A1 (en) | 2000-05-03 | 2001-11-08 | Novo Nordisk A/S | Human coagulation factor vii variants |
| US7160540B2 (en) | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
| US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
| US20030211094A1 (en) | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| RU2326126C2 (ru) | 2000-09-13 | 2008-06-10 | Ново Нордиск Хелт Кэр Аг | Полипептид фактора vii свертывания крови, его получение и применение |
| EP2226385B1 (en) | 2000-09-13 | 2013-07-10 | Novo Nordisk Health Care AG | Human Coagulation Factor VII Variants |
| AU2001291653A1 (en) | 2000-10-02 | 2002-04-15 | Novo-Nordisk A/S | Industrial-scale serum-free production of recombinant factor vii in mammalian cells |
| WO2002038162A1 (en) | 2000-11-09 | 2002-05-16 | The Scripps Research Institute | MODIFIED FACTOR VIIa |
| ES2432967T3 (es) | 2001-03-22 | 2013-12-05 | Novo Nordisk Health Care Ag | Derivados del Factor VII de coagulación |
| HUP0500060A3 (en) | 2001-09-27 | 2010-01-28 | Novo Nordisk Healthcare Ag | Human coagulation factor vii polypeptides |
| JP2005512524A (ja) | 2001-11-02 | 2005-05-12 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | ヒト凝固第ｖｉｉ因子ポリペプチド |
| JP2005530683A (ja) | 2001-12-21 | 2005-10-13 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 第ｖｉｉ因子ポリペプチドの液体組成物 |
| DE60334983D1 (de) | 2002-04-30 | 2010-12-30 | Bayer Healthcare Llc | Faktor vii oder faktor viia polypeptidvarianten |
| JP4472526B2 (ja) | 2002-09-30 | 2010-06-02 | バイエル ヘルスケア エルエルシー | 凝血活性が増加した第ＶＩＩ因子または第ＶＩＩａ因子変種 |
| EP2085470B1 (en) | 2003-03-20 | 2012-05-16 | Bayer HealthCare LLC | FVII or FVIIa variants |
| JP4915918B2 (ja) | 2003-06-19 | 2012-04-11 | バイエル ヘルスケア エルエルシー | 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種 |
| WO2005023308A1 (en) * | 2003-09-05 | 2005-03-17 | Maxygen Holdings Ltd. | Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins |
-
2004
- 2004-03-22 EP EP09075170A patent/EP2085470B1/en not_active Expired - Lifetime
- 2004-03-22 DK DK09075170.2T patent/DK2085470T3/da active
- 2004-03-22 AU AU2004221761A patent/AU2004221761B2/en not_active Ceased
- 2004-03-22 ES ES04722232T patent/ES2327044T3/es not_active Expired - Lifetime
- 2004-03-22 ES ES09075170T patent/ES2386010T3/es not_active Expired - Lifetime
- 2004-03-22 JP JP2006504332A patent/JP4847856B2/ja not_active Expired - Fee Related
- 2004-03-22 EP EP04722232A patent/EP1608745B1/en not_active Expired - Lifetime
- 2004-03-22 US US10/549,506 patent/US7771996B2/en not_active Expired - Fee Related
- 2004-03-22 AT AT04722232T patent/ATE431403T1/de not_active IP Right Cessation
- 2004-03-22 CA CA2519873A patent/CA2519873C/en not_active Expired - Fee Related
- 2004-03-22 DK DK04722232T patent/DK1608745T3/da active
- 2004-03-22 DE DE602004021099T patent/DE602004021099D1/de not_active Expired - Lifetime
- 2004-03-22 WO PCT/DK2004/000193 patent/WO2004083361A2/en not_active Ceased
-
2010
- 2010-03-25 AU AU2010201201A patent/AU2010201201A1/en not_active Abandoned
- 2010-05-05 US US12/774,560 patent/US20100330669A1/en not_active Abandoned
-
2011
- 2011-07-22 JP JP2011160400A patent/JP2012095641A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012095641A5 (enExample) | ||
| JP2006527982A5 (enExample) | ||
| JP2012105650A5 (enExample) | ||
| JP2006517089A5 (enExample) | ||
| CA2519873A1 (en) | Fvii or fviia variants | |
| RU2004134726A (ru) | Варианты полипептида фактора vii или viia | |
| JP2010523150A5 (enExample) | ||
| JP6250282B2 (ja) | 出血性障害の治療および予防的治療における非静脈内投与のためのアルブミン融合凝固因子 | |
| AU2017219044B2 (en) | Long-acting coagulation factors and methods of producing same | |
| JP6571735B2 (ja) | 止血を調節する組成物および方法 | |
| JP2004504354A5 (enExample) | ||
| AU2016280867B2 (en) | Long-acting coagulation factors and methods of producing same | |
| RU2006101391A (ru) | ВАРИАНТЫ ДОМЕНА GLa ФАКТОРА VII ИЛИ VIIa | |
| JP2013502458A5 (enExample) | ||
| JP2005270110A5 (enExample) | ||
| RU2002124129A (ru) | Молекулы, подобные фактору vii или viia | |
| PT2147096E (pt) | Polipéptidos do factor vii modificados e suas utilizações | |
| JP2005053930A5 (enExample) | ||
| JP2008502301A (ja) | ペプチドの抱合 | |
| CN104558119B (zh) | Yap蛋白抑制多肽及其应用 | |
| WO2007022784A2 (en) | Liquid factor vii composition | |
| WO2006114105A2 (en) | Use of modified factor vii for treating bleeding | |
| CN102724995B (zh) | 富含具有延伸的α链的血纤蛋白原的血纤蛋白原制备物 | |
| HUT74873A (en) | Factor vii-derived peptides | |
| JP2024539393A (ja) | 基質に結合可能なタンパク質配列の、フィブリンの集合を阻害する製品の製造における応用 |